11/17/2026 | Press release | Distributed by Public on 11/17/2026 13:02
Philadelphia Eagles quarterback Jalen Hurts is probably out for the 2026 season after being diagnosed with blood clots in both lungs, a serious health threat, BBC Sport reported Oct. 28, 2026.
How does a presumably healthy 28-year-old athlete get multiple pulmonary emboli (lung clots)?
According to the BBC, Hurts' left calf was stepped on during an Oct. 4 game. Six days later, the Eagles flew to London, and he was found to have a superficial vein thrombosis (SVT), a clot in a vein close to the surface of the leg. He played the next day and flew back to the United States. On Oct. 14, an ultrasound showed the clot had moved and he was not allowed to play. On the 19th, the Eagles said Hurts had both a deep vein thrombosis (DVT) and emboli in both lungs.
A DVT is "a formation of a clot that usually migrates from the legs, usually to the lungs," said Daniel Alape Moya, MD, a Cape Cod Healthcare pulmonologist and critical care physician. Hurts experienced two of the three most common risk factors for a DVT, he said, which are:
"They're more likely when there's a combination of factors, but they can happen to anybody," Dr. Moya said.
Clots usually happen in people older than 60, who are more likely to be less mobile and have other health problems, he said.
The risk of a superficial clot turning into DVT is about 10-20 percent, according to Dr. Moya. Superficial vessels are the ones we can see in our skin, he said.
"These clots can develop when we get an IV (intravenous line), or injury."
An SVT appears as a sore, ropey spot. Treatment may include compression stockings and NSAIDs, such as aspirin, with larger or deeper SVTs treated with anticoagulants, according to a Sept. 15, 2025, article in JAMA. In general, SVTs had been thought of as relatively benign, though they can become DVTs, according to a Feb, 19, 2024, article in Healthcare.
Risk factors are similar to those for DVTs, and include:
The Centers for Disease Control and Prevention adds active cancer and hospitalization as risk factors for DVTs and pulmonary emboli (PEs). Like SVTs, DVTs can occur in arms or legs, but are more common in legs. Symptoms of a DVT include:
Treatment usually consists of a course of anticoagulants.
Clot pieces that break off from a DVT often end up in the lungs, as opposed to the heart or brain, because "the lungs act as a net or a trap for those clots," said Dr. Moya.
An untreated pulmonary embolism can result in shock or even death, according to the National Heart, Lung and Blood Institute. Symptoms can include shortness of breath, low oxygen levels, coughing (and coughing blood) and fainting, Dr. Moya said. The NHLBI adds rapid breathing, fast heart rate, sweating and possibly anxiety.
Treatment of PEs depends upon the size of a clot and how stable the patient is, said Dr. Moya. All will get at least three months of anticoagulants, and some will be on them for a longer period. In some cases, a small catheter threaded though the venous system may be used to deliver a strong anticoagulant directly to the clot or suction out the clot. Surgery to remove a clot is "very rare," he said.
Patients will continue to have some shortness of breath for a few months after treatment begins, but they will improve. They should avoid contact sports during recovery, but physical exercise can resume at a low level at first and then gradually be increased.
If caught early, prognosis is usually good, Dr. Moya said. In some rare cases, "maybe 5 percent," a patient may develop chronic PEs.
"If you're going on a long flight or trip, every few hours stand up and walk around," advised Dr. Moya.
Women considering using hormonal birth control or who are pregnant should discuss the risk of blood clots with their primary care physician or obstetrician/gynecologist.
If someone has a PE, but no common risk factors seem involved, the patient may be tested for conditions that cause "sticky blood," Dr. Moya said. These include: Factor V deficiency, deficiency of proteins C and S, antiphospholipid syndrome and prothrombin gene mutations.
"These conditions are very uncommon," he said.